About the Company:
Achyut Healthcare Ltd is engaged in trading of Cenzure, Arpimune, Azathioprine IP, Everomimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products.
Since incorporation, Company‘s vision and mission has been to remained focused towards the pharmaceutical business of trading and supplying of superior quality products to customers based on their customizations and requirements.
Company is in the process of entering into manufacturing business on its own plants rather than outsourcing and procuring from third parties.
Pan India and Global market presence.
With the help of company’s long-standing market presence and the superior quality of products company has been able to create a pan-India India and International market presence in trading of pharmaceuticals business with the products being traded in different countries namely UAE, Kenya and Nigeria along with all over India catering to various end users, merchants, distributors and exporters.
Company currently export the products to three countries namely UAE, Kenya and Nigeria and plan to expand export operations globally.
- Mr. Mahendra Chatrabhuj Raycha (Designation: Chairman and Non-Executive Director)
- Mr. Jigen Jagdishbhai Modi (Designation: Managing Director and Chief Financial Officer)
Objectives of the Issue:
Offer for Sale: (Rs. 4 cr )
- Funding purchases of machineries and equipment;
- General Corporate Purposes.
Proposed Schedule of Implementation:
Financials of the Company:
|(in Crores)||FY 19||FY 20||FY 21||31st August 21|
Valuation of Peer Group Companies:
|Company Name||Face Value||EPS||PE Ratio||RoNW||NAV|
|Achyut Healthcare Ltd||10||0.30||66.66||3.41%||8.68|
|Earum Pharmaceuticals Ltd||2||0.028||392.86||0.61%||4.702|
|Vaishali Pharma Ltd||10||0.99||33.54||4.63%||21.25|
|Chandra Bhagat Pharma Ltd||10||0.25||366.0||0.73%||34.29|
|Issue Opens on||17th March 2022|
|Issue Closes on:.||22nd March 2022|
|Issue Size||Rs.20.88 cr|
|Market Cap||Rs.77.13 cr|
|Listing at||NSE SME|
|Equity Shares Offered||27,84,000|
|Equity Shares Prior||75,00,000|
|Equity Shares after the issue||1,02,84,000|
Also Read : List of Upcoming IPO’s in India.
Also Read : List of Upcoming SME IPO’s in India.
|Finalization of Basis of Allotment||on or Before 25th March 2022|
|Initiation of Refunds||on or Before 28th March 2022|
|Credit of Equity Shares:||on or Before 29th March 2022|
|Listing Date:||on or Before 30th March 2022|
IPO Valuation Parameters:
|Earnings Per Share (EPS)||Price To Earnings ratio (PE)||Return on Net Worth (RoNW)||Net Asset Value (NAV)|